---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-007001"
form_type: "8-K"
ticker: "BFRI"
cik: "0001858685"
company_name: "Biofrontera Inc."
filed_at: "2023-03-08T23:59:59+00:00"
generated_at: "2026-06-18T08:51:38.188743+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Biofrontera reports Q4 2022 rev $10.1M (+11% YoY); FY rev $28.7M (+19%); guides 25% growth in 2023

## Summary
- Total revenue Q4 2022 $10.1M (+11% YoY); FY 2022 $28.7M (+19% YoY).
- Net loss Q4 $2.8M vs $14.5M in Q4 2021; FY net loss $0.64M vs $37.7M in 2021.
- Adjusted EBITDA negative $4.4M in Q4 and negative $18.1M for FY 2022.
- Guidance: FY 2023 revenue growth at least 25%; expects cash flow positive within ~2 years.
- Expanding salesforce to 50-55 over next couple of years; will stop providing preliminary quarterly revenue.

## SEC filing metadata
- accession: 0001493152-23-007001
- form_type: 8-K
- ticker: BFRI
- cik: 0001858685
- company_name: Biofrontera Inc.
- filed_at: 2023-03-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1858685/000149315223007001/0001493152-23-007001-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1858685/000149315223007001/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-007001
- JSON: https://secwatch.observer/filing/0001493152-23-007001.json
- Plain text: https://secwatch.observer/filing/0001493152-23-007001.txt

## Key facts
- Earnings Releases
  Biofrontera Inc. reported fourth quarter and fiscal year ended December 31, 2022 results: revenue $10.1 million, net income $2.8 million. Guidance raised.
  - Period: fourth quarter and fiscal year ended December 31, 2022
  - Revenue: $10.1 million
  - Net income: $2.8 million
  - Guidance: raised
  - Result: reported results
  source text: at least 25% over last year positioning us well to be cashflow positive within approximately two years.” Fourth Quarter Financial Results Fourth quarter 2022 total revenues of $10.1 million, compared with $9.2 million in the fourth quarter of 2021. The increase was driven by continued growth in the sales of Ameluz, partially offset by shipping delays and some sales
  evidence_url: https://www.sec.gov/Archives/edgar/data/1858685/000149315223007001/0001493152-23-007001-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.